Authors: Fizazi, K Caliandro, R Soulie, P Fandi, A Daniel, C Bedin, A Doubre, H Viala, J Rodier, JM Trandafir, L Le Chevalier, T Cvitkovic, E Armand, JP Ruffie, P

Citation: K. Fizazi et al., Combination raltitrexed (Tomudex (R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma, EUR J CANC, 36(12), 2000, pp. 1514-1521

Authors: Fandi, A Bachouchi, M Azli, N Taamma, A Boussen, H Wibault, P Eschwege, F Armand, JP Simon, J Cvitkovic, E

Citation: A. Fandi et al., Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type, J CL ONCOL, 18(6), 2000, pp. 1324-1330

Authors: Fizazi, K Ducreux, M Ruffie, P Bonnay, M Daniel, C Soria, JC Hill, C Fandi, A Poterre, M Smith, M Armand, JP

Citation: K. Fizazi et al., Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer, J CL ONCOL, 18(11), 2000, pp. 2293-2300

Authors: Hasbini, A Mahjoubi, R Fandi, A Chouaki, N Taamma, A Lianes, P Cortes-Funes, H Alonso, S Armand, JP Cvitkovic, E Raymond, E

Citation: A. Hasbini et al., Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type, ANN ONCOL, 10(4), 1999, pp. 421-425

Authors: Taamma, A Fandi, A Azli, N Wibault, P Chouaki, N Hasbini, A Couteau, C Armand, JP Cvitkovic, E

Citation: A. Taamma et al., Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin,and cisplatin for patients with locally advanced, metastatic, or recurrentundifferentiated carcinoma of the nasopharyngeal type, CANCER, 86(7), 1999, pp. 1101-1108